Holen Sie sich die Stockscreener-App
1.20
0.83%
-0.01
Opko Health Inc Aktie (OPK) Neueste Nachrichten
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - The Globe and Mail
OPKO Health (OPK) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Finviz
Opko Health, Inc. (OPK) Investor Outlook: Unpacking The 189.30% Potential Upside - DirectorsTalk Interviews
11 Best High Return Penny Stocks to Buy Right Now - Insider Monkey
Esoteric Testing Market: Generated Opportunities and Future - openPR.com
Why OPKO Health Inc. stock is favored by top institutionsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
OPKO Health, Inc. to Announce 2025 Financial Results on February 26, 2026 - Quiver Quantitative
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - OPKO Health, Inc.
What is the long term forecast for OPKO Health Inc. stockWall Street Watch & AI Enhanced Trade Execution Alerts - mfd.ru
OPKO Health Insider Ups Holding During Year - Yahoo Finance
What hedge fund activity signals for OPKO Health Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Opko Health stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
OPKO Health, Inc. (OPK) Stock Analysis: Exploring A 191.67% Potential Upside - DirectorsTalk Interviews
Swing Trade: What is OPKO Health Incs 5 year growth outlookWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Insider Monkey
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria
Opko Health and Entera Bio expand partnership to advance first-in-class oral long acting PTH tablet for patients with hypoparathyroidism - marketscreener.com
OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com
Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times
Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism - TradingView
OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider
Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire
Market Review: Is OPKO Health Inc likely to announce a buybackJuly 2025 Volume & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha
EV Market: Will OPKO Health Inc benefit from seasonality2025 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn
Analyst Calls: Does RAMP align with a passive investing strategyCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn
OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts - MarketBeat
OPKO Health (NASDAQ:OPK) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Update Recap: What is OPKO Health Incs 5 year growth outlookJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Movement Recap: What drives Simulations Plus Incs stock priceQuarterly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Opko Health, Inc. (OPK) Stock Analysis: Exploring A Potential 177.99% Upside - DirectorsTalk Interviews
Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burg... - ADVFN
Options Flow: What is the long term forecast for OPKO Health Inc stockPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health (NASDAQ:OPK) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
OPK: Therapeutics-focused strategy, key partnerships, and innovative pipeline drive growth - TradingView — Track All Markets
Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns - Yahoo Finance
Block Trades: Is OPKO Health Inc forming a double bottom2025 AllTime Highs & Accurate Buy Signal Notifications - baoquankhu1.vn
Assessing OPKO Health (OPK) Valuation After Diagnostics Refocus And Mixed Share Price Performance - Yahoo Finance
What are the future prospects of OPKO Health Inc.Exit Point & Smart Allocation Stock Tips - bollywoodhelpline.com
Opko Health, Inc. (OPK) Stock Analysis: Exploring A 167% Potential Upside For Investors - DirectorsTalk Interviews
Bearish Setup: Should I hold or sell OPKO Health Inc nowWeekly Stock Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Is OPKO Health Inc. stock undervalued vs historical averagesQuarterly Trade Summary & Low Risk Investment Opportunities - ulpravda.ru
Is OPKO Health Inc. stock vulnerable to regulatory risks2025 Dividend Review & Advanced Technical Analysis Signals - Улправда
Is OPKO Health Inc. stock supported by innovation pipelineShare Buyback & Real-Time Chart Pattern Alerts - Улправда
Why OPKO Health Inc. stock is considered a top pick2025 Fundamental Recap & Weekly Watchlist for Hot Stocks - Улправда
Is OPKO Health Inc. stock attractive for income investorsQuarterly Portfolio Review & Fast Exit/Entry Strategy Plans - Улправда
Setup Watch: Why OPKO Health Inc. stock appeals to analystsTrade Risk Assessment & Weekly High Return Forecasts - Улправда
Does OPKO Health Inc. stock trade at a discount to peersJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
How OPKO Health Inc. (XCY) stock trades after earningsEarnings Forecast Updates & Low Entry Cost Investments - Улправда
0.01%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):